Table 1.
Results of the effectiveness algorithm, overall and by index medication
| Criterion | Total (N = 7797), n (%) | Adalimumab (n = 1899), n (%) | Certolizumab pegol (n = 124), n (%) | Etanercept (n = 4188), n (%) | Golimumab (n = 170), n (%) | Infliximab (n = 1416), n (%) |
|---|---|---|---|---|---|---|
| Criterion 1: PDC ≥0.8 for index TNFi | 3362 (43.1%) | 795 (41.9%) | 35 (28.2%) | 1721 (41.1%) | 65 (38.2%) | 746 (52.7%) |
| Criterion 2: Patients with no biologic switch or addition | 6286 (80.6%) | 1528 (80.5%) | 99 (79.8%) | 3339 (79.7%) | 133 (78.2%) | 1187 (83.8%) |
| Criterion 3: Patients with no addition of a new csDMARD | 6705 (86.0%) | 1604 (84.5%) | 103 (83.1%) | 3621 (86.5%) | 137 (80.6%) | 1240 (87.6%) |
| Criterion 4: Patients with no increase in index TNFi dose or frequency | 7019 (90.0%) | 1738 (91.5%) | 116 (93.5%) | 4151 (99.1%) | 170 (100.0%) | 844 (59.6%) |
| Criterion 5: Patients with no more than one glucocorticoid joint injection | 6483 (83.1%) | 1604 (84.5%) | 96 (77.4%) | 3591 (85.7%) | 140 (82.4%) | 1052 (74.3%) |
| Criterion 6: Patients with no increase in dose of oral glucocorticoid | 6907 (88.6%) | 1702 (89.6%) | 112 (90.3%) | 3734 (89.2%) | 152 (89.4%) | 1207 (85.2%) |
| Total number of patients with treatment response | 2337 (30.0%) | 586 (30.9%) | 24 (19.4%) | 1418 (33.9%) | 56 (32.9%) | 253 (17.9%) |
Abbreviations: csDMARD Conventional synthetic disease-modifying antirheumatic drug, PDC Proportion of days covered, TNFi Tumor necrosis factor inhibitors